Dexmedetomidine Reduces Agitation and Accelerates Recovery in Non-Intubated ICU Patients with Hyperactive Delirium: Insights from the 4D Trial

Highlights

The 4D trial provides robust evidence for the use of dexmedetomidine in managing hyperactive delirium among non-intubated patients. Key takeaways include:

• Dexmedetomidine significantly improved a joint primary endpoint encompassing agitation duration, delirium duration, and the risk of intubation.
• The median duration of agitation was reduced by approximately 50%, falling from 2 hours in the placebo group to 1 hour in the dexmedetomidine group.
• The study was terminated early due to clear evidence of efficacy at the preplanned interim analysis.
• Safety profiles regarding bradycardia and hypotension were comparable between the dexmedetomidine and placebo groups in this specific cohort.